Sygnature Discovery Ltd.

https://www.sygnaturediscovery.com

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services company. Private equity-backed since 2017, we operate fully-enabled research facilities in Nottingham and Alderley Park, UK, housing over 200 research scientists (over 80% with PhDs) and have an office presence in Cambridge, Massachusetts, USA. Our experienced drug hunters possess all the professional skills and know-how required to undertake the most demanding of research programmes and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 14 drug candidates to our clients which have subsequently entered the clinic (Phases I, II and III). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade. *

	Start	2011-09-05 renamed
	Predecessor	Sygnature Chemical Services Ltd.
	Industry	drug discovery services
	Industry 2	ADME services
	Person	Hirst, Simon (Sygnature Discovery 201112 CEO + Founder)
	Person 2	Lindstrom, Andy (Sygnature Discovery 201807c– Director of Marketing before Siemens + Experian)

	Region	Nottingham, Nottinghamshire
	Country	United Kingdom (GB)
	Street	Pennyfoot Street BioCity Nottingham, The Discovery Building
	City	NG1 1GR Nottingham
	Tel	+44-115-941-5401
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2018-11-27)

		* Document for ï¿½About Sectionï¿½: Sygnature Discovery Ltd.. (2/15/19). "Press Release: Sygnature Discovery Starts 2019 with Two Senior Appointments – Dr Allan Jordan and Ms Louisa Jordison". Nottingham.

		Record changed: 2021-03-25